Related Experiment Video
Updated: Dec 21, 2025
Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
Published on: June 17, 2025
miR-1291 Functions as a Potential Serum Biomarker for Bullous Pemphigoid
Li Qiu1, Liming Zhang1, Ruiqun Qi1
1Department of Dermatology, The First Hospital of China Medical University, National Health Commission Key Laboratory of Immunodermatology, Key Laboratory of Immunodermatology of Ministry of Education, Shenyang, Liaoning, China.
Background:
Bullous pemphigoid (BP) is a common T helper 2- (Th2-) dominated autoimmune blistering skin disease with significant mortality. MicroRNAs (miRNAs), which are endogenous noncoding RNA molecules, have been reported to be potential biomarkers for some autoimmune diseases; however, to date, there exist no reports on serum expression profiles of miRNAs in BP patients.
Methods:
A RNA quantitative PCR- (qPCR-) based array was conducted on sera from 20 active BP patients and 20 healthy controls for screening of miRNAs. Significantly dysregulated miRNAs were validated with use of qPCR as performed on sera samples of 45 active BP patients and 60 healthy controls. Serum CCL17, anti-BP180, and anti-BP230 levels were measured with use of ELISA.
Results:
Relative baseline expression levels of serum miR-1291 were significantly upregulated in the 45 BP patients as compared with the 60 healthy controls (P < 0.001) and significantly decreased in the disease control stage (n = 13, P = 0.006). In addition, these baseline miR-1291 levels showed a significant positive correlation with the baseline levels of serum CCL17 (P < 0.001) and anti-BP180 (n = 38, P = 0.024). Like that observed for miR-1291, baseline levels of serum CCL17 were also significantly elevated in the 45 BP patients compared with the 60 healthy controls (P < 0.001) and significantly decreased in the disease control stage (n = 13, P = 0.002). However, for anti-BP180, baseline serum levels were significantly elevated in only 38 of the 45 BP patients and significantly decreased in the disease control stage (n = 10, P = 0.004).
Conclusions:
Relative expression levels of serum miR-1291 can reflect disease activity of BP. miR-1291 may function as an important new serum biomarker for BP.
Insights
Serum miR-1291 levels can indicate bullous pemphigoid (BP) disease activity. This microRNA (miRNA) shows potential as a novel serum biomarker for diagnosing and monitoring BP.
Area of Science:
- Immunodermatology
- Molecular Biology
- Biomarker Discovery
Background:
- Bullous pemphigoid (BP) is a severe autoimmune blistering skin disease.
- T helper 2 (Th2) immune responses dominate BP pathogenesis.
- MicroRNAs (miRNAs) are investigated as potential biomarkers for autoimmune diseases.
Purpose of the Study:
- To investigate serum microRNA (miRNA) expression profiles in bullous pemphigoid (BP) patients.
- To identify potential serum biomarkers for BP disease activity.
Main Methods:
- Serum samples from 20 active BP patients and 20 healthy controls were analyzed using miRNA quantitative PCR (qPCR) arrays.
- Dysregulated miRNAs were validated in 45 BP patients and 60 healthy controls.
- Serum levels of CCL17, anti-BP180, and anti-BP230 were measured by ELISA.
Main Results:
- Serum miR-1291 was significantly upregulated in active BP patients compared to controls.
- miR-1291 levels decreased during disease remission.
- Baseline miR-1291 positively correlated with serum CCL17 and anti-BP180 levels.
Conclusions:
- Serum miR-1291 expression levels correlate with bullous pemphigoid (BP) disease activity.
- miR-1291 is a promising novel serum biomarker for BP.
